HRP20171993T1 - Varijante ljudskog gdnf - Google Patents

Varijante ljudskog gdnf Download PDF

Info

Publication number
HRP20171993T1
HRP20171993T1 HRP20171993TT HRP20171993T HRP20171993T1 HR P20171993 T1 HRP20171993 T1 HR P20171993T1 HR P20171993T T HRP20171993T T HR P20171993TT HR P20171993 T HRP20171993 T HR P20171993T HR P20171993 T1 HRP20171993 T1 HR P20171993T1
Authority
HR
Croatia
Prior art keywords
variant
seq
rgqrgkqrgcvltaihlnvtdlglgyetkeelifrycsgscdaaettyd
human gdnf
gdnf
Prior art date
Application number
HRP20171993TT
Other languages
English (en)
Croatian (hr)
Inventor
Donmienne Doen Mun Leung
Jirong Lu
Kalpana Mahesh Merchant
Mahmoud Ghanem
Linda Maureen O'bryan
Rosamund Carol Smith
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20171993T1 publication Critical patent/HRP20171993T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • External Artificial Organs (AREA)
HRP20171993TT 2011-04-11 2012-04-03 Varijante ljudskog gdnf HRP20171993T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161474024P 2011-04-11 2011-04-11
PCT/US2012/031927 WO2012141936A1 (en) 2011-04-11 2012-04-03 Variants of human gdnf
EP12712874.2A EP2696889B1 (en) 2011-04-11 2012-04-03 Variants of human gdnf

Publications (1)

Publication Number Publication Date
HRP20171993T1 true HRP20171993T1 (hr) 2018-02-09

Family

ID=45932578

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171993TT HRP20171993T1 (hr) 2011-04-11 2012-04-03 Varijante ljudskog gdnf

Country Status (28)

Country Link
US (1) US9243046B2 (enExample)
EP (1) EP2696889B1 (enExample)
JP (1) JP6093345B2 (enExample)
KR (1) KR101554799B1 (enExample)
CN (1) CN103635201B (enExample)
AU (1) AU2012243178B2 (enExample)
BR (1) BR112013026004B1 (enExample)
CA (1) CA2833158C (enExample)
CY (1) CY1119750T1 (enExample)
DK (1) DK2696889T3 (enExample)
EA (1) EA025129B1 (enExample)
ES (1) ES2656020T3 (enExample)
HR (1) HRP20171993T1 (enExample)
HU (1) HUE036239T2 (enExample)
IL (1) IL228102A (enExample)
LT (1) LT2696889T (enExample)
ME (1) ME02849B (enExample)
MX (1) MX337206B (enExample)
NO (1) NO2696889T3 (enExample)
PL (1) PL2696889T3 (enExample)
PT (1) PT2696889T (enExample)
RS (1) RS56639B1 (enExample)
SG (1) SG193483A1 (enExample)
SI (1) SI2696889T1 (enExample)
TW (1) TWI583698B (enExample)
UA (1) UA112981C2 (enExample)
WO (1) WO2012141936A1 (enExample)
ZA (1) ZA201306556B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3454886A1 (en) 2016-05-13 2019-03-20 Instituto de Medicina Molecular Methods of treating diseases associated with ilc3 cells
US20230022970A1 (en) * 2019-12-19 2023-01-26 Transfert Plus, Société En Commandite Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies
EP4347645A1 (en) 2021-06-03 2024-04-10 Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud Foundation Neuro-mesenchyme units control ilc2 and obesity via a brain-adipose circuit
CN116606365A (zh) * 2023-02-24 2023-08-18 肇庆医学高等专科学校 一种gdnf新型变体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006116A1 (en) 1991-09-20 1993-04-01 Syntex-Synergen Neuroscience Joint Venture Glial derived neurotrophic factor
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US6042579A (en) 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
DE19816186A1 (de) 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
FI20070808A0 (fi) 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
CN101775072B (zh) * 2008-05-21 2012-09-05 王尚武 一种融合穿透肽的神经细胞营养因子gdnf
WO2010090523A1 (en) * 2009-02-06 2010-08-12 Pepscan Systems B.V. Truncated cystine-knot proteins

Also Published As

Publication number Publication date
JP2014512369A (ja) 2014-05-22
NZ614325A (en) 2015-07-31
CN103635201B (zh) 2016-11-09
AU2012243178B2 (en) 2016-09-29
SI2696889T1 (en) 2018-01-31
EP2696889B1 (en) 2017-11-15
EP2696889A1 (en) 2014-02-19
CY1119750T1 (el) 2018-06-27
JP6093345B2 (ja) 2017-03-08
CN103635201A (zh) 2014-03-12
US9243046B2 (en) 2016-01-26
BR112013026004A2 (pt) 2016-11-29
DK2696889T3 (en) 2018-01-22
KR101554799B1 (ko) 2015-09-21
PL2696889T3 (pl) 2018-04-30
US20130324474A1 (en) 2013-12-05
MX2013011919A (es) 2014-03-27
CA2833158A1 (en) 2012-10-18
ZA201306556B (en) 2015-03-25
IL228102A (en) 2017-04-30
ES2656020T3 (es) 2018-02-22
HUE036239T2 (hu) 2018-06-28
TW201245220A (en) 2012-11-16
ME02849B (me) 2018-01-20
UA112981C2 (uk) 2016-11-25
BR112013026004B1 (pt) 2020-09-29
PT2696889T (pt) 2018-02-05
LT2696889T (lt) 2018-02-12
KR20130131470A (ko) 2013-12-03
EA201370204A1 (ru) 2014-02-28
MX337206B (es) 2016-02-17
SG193483A1 (en) 2013-10-30
WO2012141936A1 (en) 2012-10-18
IL228102A0 (en) 2013-09-30
NO2696889T3 (enExample) 2018-04-14
AU2012243178A1 (en) 2013-09-05
TWI583698B (zh) 2017-05-21
RS56639B1 (sr) 2018-03-30
EA025129B1 (ru) 2016-11-30
CA2833158C (en) 2018-07-17

Similar Documents

Publication Publication Date Title
HRP20191957T1 (hr) Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
JP2013520405A5 (enExample)
SA520411119B1 (ar) تركيبات جسيم شحمي تشمل عقاقير مكونة من حمض ضعيف واستخداماتها
JP2014530220A5 (enExample)
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
JP2015057451A5 (enExample)
DOP2011000343A (es) Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral
JP2015517488A5 (enExample)
JP2012041342A5 (enExample)
MX2012004625A (es) Peptidos utiles en el tratamiento y/o cuidado de la piel, mucosas y/o cabello y su uso en composiciones cosmeticas o farmaceuticas.
UA108363C2 (uk) Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
EA201101518A1 (ru) Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии
SI2709613T1 (en) Procedures for the treatment of HCV
HRP20140011T1 (hr) Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja
RU2017114352A (ru) АНТАГОНИСТЫ ИНТЕГРИНА ανβ6
BR112015010396A2 (pt) terapia de combinação
MX2017012393A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
ME02841B (me) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
HRP20211749T1 (hr) Pentanske kiseline supstituirane pirolo-[2-3,b]pirimidin-piridinima za liječenje virusnih infekcija influencom
EA201171087A1 (ru) СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ
EA201591701A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
HRP20191723T1 (hr) Nukleotid dims0-150 za primjenu u liječenju kroničnog aktivnog ulceroznog kolitisa
EA201500513A1 (ru) Продукт сомикронизации, включающий ацетат улипристала
JP2009500045A5 (enExample)